Sunshine Biopharma, Inc.

SBFM • Drug Manufacturers - Specialty & Generic

$1.14

▲ +0.03 (+2.70%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$1.09M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.04Liquidez saludable · 4.17Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:41 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$1.14

Change2.70%

Shares Out952.43K

Market Cap$1.09M

Enterprise Value$-12.66M

52W Range1.10 - 24.30

Beta1.31

P/E-0.18

P/S0.07

P/B0.04

P/FCF-0.21

EV/Sales-0.76

Price$1.14

Change2.70%

Shares Out952.43K

Market Cap$1.09M

Enterprise Value$-12.66M

52W Range1.10 - 24.30

Beta1.31

P/E-0.18

P/S0.07

P/B0.04

P/FCF-0.21

EV/Sales-0.76

EV/EBITDA2.23

EV/FCF2.45

Earnings Yield-570.33%

FCF Yield-475.82%

Dividend Yield0.00%

Gross Margin32.84%

Oper. Margin-12.34%

Profit Margin-16.46%

Debt/Eq0.04

Current Ratio4.17

Quick Ratio2.08

Volume181.58K

Avg Volume1.66M

EPS Surprise0.00

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

95/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.04Liquidez saludable · 4.17Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

SBFM

Analyst sentiment

Based on 1 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 2/15/2022

Industria: Drug Manufacturers - Specialty & Generic

P/B i: 0.04

Deuda / Patrimonio i: 0.04

Margen operativo: -12.34%

Margen neto: -16.46%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.04

Ratio corriente: 4.17

Ratio rápido: 2.08

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 2 venta interna de alto volumens detectadas

NATAN DAVID

Transacción: 08/07/2026

COMPRA

Cambio

+58,300

Precio

Not reported

Presentación

08/11/2026

Tipo

COMPRA

NATAN DAVID

Transacción: 04/14/2026

COMPRA

Cambio

+100,000

Precio

Not reported

Presentación

04/14/2026

Tipo

COMPRA

Roy Michel

Transacción: 01/13/2025

OTRO

Cambio

Precio

Not reported

Presentación

01/21/2025

Tipo

OTRO

Insider	Tipo	Cambio	Precio	Transacción	Presentación
NATAN DAVID	COMPRA	+58,300	Not reported	08/07/2026	08/11/2026
NATAN DAVID	COMPRA	+100,000	Not reported	04/14/2026	04/14/2026
Roy Michel	OTRO	0	Not reported	01/13/2025	01/21/2025
Slilaty Steve N.	COMPRA	+100,000	$0.10	03/04/2024	03/05/2024
Slilaty Steve N.	COMPRA	+20,000	$0.10	02/08/2024	02/12/2024
Beaudoin Marc	OTRO	0	Not reported	01/26/2024	02/09/2024
Sebaaly Camille	COMPRA	+30,000	$0.76	11/30/2022	12/02/2022
Chamoun Malek	VENTA	0	Not reported	10/20/2022	10/26/2022
Sebaaly Camille	COMPRA	+25,000	$1.22	06/03/2022	06/06/2022
Slilaty Steve N.	VENTA	-990,000	$0.10	02/18/2022	02/22/2022
Keller Andrew Mark	VENTA	0	Not reported	02/10/2022	02/18/2022
NATAN DAVID	VENTA	0	Not reported	02/10/2022	02/18/2022
Kiderchah Rabi	VENTA	0	Not reported	10/31/2021	12/16/2021
Kish James Daniel	OPCIÓN	0	Not reported	10/31/2021	12/14/2021
TELSEY ANDREW I	VENTA	0	Not reported	10/31/2021	12/09/2021
Sebaaly Camille	COMPRA	+20,000,000	$0.00	01/06/2021	02/16/2021
Slilaty Steve N.	COMPRA	+20,000,000	$0.00	01/06/2021	02/16/2021
MERZOUKI ABDERRAZZAK	COMPRA	+20,000,000	$0.00	01/06/2021	02/16/2021
Sebaaly Camille	VENTA	-323,673	$0.00	12/31/2019	07/15/2020
Sebaaly Camille	COMPRA	+1,300,000	$0.00	12/19/2019	07/15/2020

Sobre la compañía

Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.

Fuente - Link

Competidores

ACXP BFRI CHEK EVOK HCWB IINN LUCY PFSA SNOA YCBD

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions

FORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin®.

Accesswire

Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer

K1.1 mRNA demonstrated tumor-suppressing activity as a single agent in multiple in vivo hepatocellular carcinoma models Program targets a tumor suppressor frequently mutated in difficult-to-treat lung, pancreatic and liver cancers Next phase will combine K1.1 mRNA with a cancer vaccine in NSCLC with the goal of converting "cold" tumors into "hot" tumors FORT LAUDERDALE, FL / ACCESS Newswire / August 26, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company offering and researching life-saving medicines across multiple therapeutic areas including oncology and antivirals, today provided an update and outlined next plans for its oncology project, the K1.1 mRNA lipid nanoparticle (LNP) program. The gene encoding the K1.1 mRNA is a tumor suppressor that is frequently mutated in a variety of cancers, including hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), and pancreatic cancer.

Accesswire

Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market

Global anti-hypertensive drug market projected to reach $37.24 billion by 2034 Enalapril is a widely prescribed ACE inhibitor used to treat hypertension, heart failure and left ventricular dysfunction Sunshine Biopharma expects Enalapril tablets in four dosage strengths to begin shipping to Canadian pharmacies by year-end 2026 FORT LAUDERDALE, FL / ACCESS Newswire / August 19, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Enalapril tablets 2.5mg, 5mg, 10mg and 20mg for the Canadian market. Enalapril is the generic equivalent of the brand name, Vasotec®.

Accesswire

Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market

Sunshine Biopharma's Amoxicillin now shipping to Canadian pharmacies in multiple dosages and strengths Launch expands Sunshine Biopharma's growing portfolio of essential prescription medications Global Amoxicillin market projected to reach approximately $6.4 billion by 2031 FORT LAUDERDALE, FL / ACCESS Newswire / August 7, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the launch of its generic Amoxicillin formulation in the Canadian market. This strategic expansion reinforces Sunshine Biopharma's commitment to providing affordable, high-quality antibiotics to patients across Canada.

Accesswire

Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval

Dienogest is first-line therapy for pelvic pain associate with endometriosis The endometriosis treatment market is projected to reach $5.2 billion by 2034 FORT LAUDERDALE, FL / ACCESS Newswire / August 4, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Dienogest tablets of 2mg for the Canadian market. Dienogest is the generic equivalent of the brand name, Visanne®.

Accesswire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-13	-2.5	-2.5	0
2026-04-04	-2.5	-2.5	0
2026-04-03	-2.7	-3	-0.3
2025-11-13	-0.13	-0.19	-0.06
2025-08-12	-0.11	-0.39	-0.28
2025-03-31	0.01	-1.01	-1.02
2024-11-05	-535	-0.94	534.06
2024-08-19	-0.6	-9.94	-9.34
2024-05-20	-160	-40	120
2024-03-28	-0.6	-1	-0.4
2023-11-13	-1.2	-0.8	0.4
2023-08-11	-160	-40	120